Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Clinical Trial to Evaluate the Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects

NCT06921486 is registered in ClinicalTrials.gov with Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06921486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06921486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Clinical Trial to Evaluate the Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects
Lead sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
March 31, 2025
Completion date
December 31, 2026
Enrollment
1,003 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

obesity and overweight